[go: up one dir, main page]

AR066198A1 - Anticuerpos anti ige apoptoticos - Google Patents

Anticuerpos anti ige apoptoticos

Info

Publication number
AR066198A1
AR066198A1 ARP080101217A ARP080101217A AR066198A1 AR 066198 A1 AR066198 A1 AR 066198A1 AR P080101217 A ARP080101217 A AR P080101217A AR P080101217 A ARP080101217 A AR P080101217A AR 066198 A1 AR066198 A1 AR 066198A1
Authority
AR
Argentina
Prior art keywords
pta
ige
apoptotic
antibody
vector
Prior art date
Application number
ARP080101217A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39709011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR066198A1 publication Critical patent/AR066198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos anti-IgE apoptoticos, con el ácido nucleico que los codifica, con composiciones terapéuticas de éstos y con su uso en el tratamiento de trastornos mediados por IgE. Asimismo se revela un vector que comprende el ácido nucleico, célula huésped que incluye dicho vector, un proceso para producir un anticuerpo anti-IgE/M1' apoptotico, un animal transgénico que expresa el segmento M1' humano de IgE e un hibridoma murino seleccionado del grupo PTA-8260, PTA-8261, PTA-8262, PTA-8263, PTA-8264, PTA8265, PTA-8266, PTA-8267, PTA-8268, PTA-8269, PTA-8270. Reivindicacion 1: Un anticuerpo anti-IgE/M1' que se une específicamente al segmento M1' de IgE y que induce la apoptosis en células B que expresan IgE.
ARP080101217A 2007-03-22 2008-03-25 Anticuerpos anti ige apoptoticos AR066198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89633907P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
AR066198A1 true AR066198A1 (es) 2009-08-05

Family

ID=39709011

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101217A AR066198A1 (es) 2007-03-22 2008-03-25 Anticuerpos anti ige apoptoticos

Country Status (31)

Country Link
US (6) US8071097B2 (es)
EP (2) EP2132230B1 (es)
JP (3) JP5723594B2 (es)
KR (1) KR101555068B1 (es)
CN (2) CN103554263B (es)
AR (1) AR066198A1 (es)
AU (1) AU2008228778B2 (es)
BR (1) BRPI0808291A2 (es)
CA (1) CA2681341A1 (es)
CL (1) CL2008000839A1 (es)
CO (1) CO6241138A2 (es)
CR (1) CR11035A (es)
CY (1) CY1115257T1 (es)
DK (1) DK2132230T3 (es)
EC (1) ECSP099645A (es)
ES (1) ES2478242T3 (es)
HR (1) HRP20140661T1 (es)
IL (1) IL200752A0 (es)
MA (1) MA31312B1 (es)
MX (1) MX2009010092A (es)
NZ (1) NZ580553A (es)
PE (2) PE20090726A1 (es)
PL (1) PL2132230T3 (es)
PT (1) PT2132230E (es)
RS (1) RS53402B (es)
RU (1) RU2500686C2 (es)
SI (1) SI2132230T1 (es)
TW (1) TWI464178B (es)
UA (1) UA102994C2 (es)
WO (1) WO2008116149A2 (es)
ZA (1) ZA201205868B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
AU2006297304B2 (en) 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
NZ588853A (en) * 2008-03-31 2013-07-26 Genentech Inc Compositions and methods for treating and diagnosing asthma
MX2011008971A (es) * 2009-02-25 2012-02-21 Alfur F Hung Anticuerpos anti-cemx que pueden enlazarse a mlge humana en linfocitos b.
AU2014203008B2 (en) * 2009-02-25 2016-03-31 Academia Sinica Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
ES2495367T3 (es) * 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticuerpos monoclonales de ERG
WO2010128265A2 (fr) 2009-05-07 2010-11-11 Stallergenes S.A. Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CA2817380C (en) 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US9795618B2 (en) * 2014-02-28 2017-10-24 University Of Cincinnati Methods and compositions for suppressing IgE-mediated anaphylaxis
US10086005B2 (en) 2011-04-12 2018-10-02 University Of Cincinnati Methods for suppressing allergic reactions
CA2838952C (en) 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
LT2771031T (lt) 2011-10-28 2018-08-27 Prothena Biosciences Limited Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
MX360778B (es) 2012-01-27 2018-11-16 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen alfa-sinucleína.
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
WO2013158274A1 (en) * 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
HRP20250525T1 (hr) 2012-05-18 2025-06-20 Genentech, Inc. Visokokoncentrirane formulacije monoklonskog protutijela
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
WO2014041544A1 (en) * 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2970454A4 (en) * 2013-03-13 2016-08-31 Academia Sinica Taiwan ANTIBODIES SPECIFIC FOR A NEW EPITOPE ON CEMX OF HUMAN MEMBRANE-TREATED IGE AND USE FOR THE TREATMENT OF IGE-MEDIATED ILLNESSES
CA2907776C (en) * 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3012727B1 (en) * 2013-06-19 2019-07-03 Sony Corporation Display control device, display control method, and program
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
US20170101460A1 (en) * 2014-01-10 2017-04-13 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
CN106062000B (zh) 2014-02-28 2021-05-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗皮肤感染的方法
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
JP6397938B2 (ja) * 2014-06-17 2018-09-26 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球のＣＤ２３と架橋するが肥満細胞を感作しないヒト化抗ＩｇＥ抗体
EP3207057A2 (en) * 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
CA2969870A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CA2969877A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
ES2807591T3 (es) * 2015-04-13 2021-02-23 Pfizer Receptores de antígeno quimérico dirigidos a antígeno de maduración de células B
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
WO2017011728A1 (en) * 2015-07-15 2017-01-19 Washington University ANTIBODIES TO TUMOR ASSOCIATED COMPLEX N-GLYCANS WITH TERMINAL GlcNAcBeta RESIDUES AND METHODS OF USE THEREOF
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
WO2017132457A1 (en) * 2016-01-28 2017-08-03 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
EP4276108A3 (en) 2016-04-27 2024-01-24 AbbVie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
ES3034904T3 (en) 2016-07-18 2025-08-27 Univ Ramot Modular platform for targeted therapeutics
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
EP3558366A1 (en) 2016-12-22 2019-10-30 H. Hoffnabb-La Roche Ag Methods and formulations for reducing reconstitution time of lyophilized polypeptides
ES2949364T3 (es) 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
RU2736974C1 (ru) * 2017-04-21 2020-11-23 Ами Фарм Ко., Лтд. Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079992A1 (en) 2017-10-31 2019-05-09 Oneness Biotech Co. Ltd. Treating ige-mediated allergic diseases
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US12410233B2 (en) 2018-01-08 2025-09-09 Gi Innovation, Inc. Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
CN111787947A (zh) * 2018-02-09 2020-10-16 豪夫迈·罗氏有限公司 用于肥大细胞介导的炎性疾病的治疗和诊断方法
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
KR20210084485A (ko) * 2018-10-01 2021-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 다중 항체 이소타입의 동시 분리능을 갖는 고 특이성 및 민감도 면역 흡착제 진단 분석
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
SG11202109002XA (en) * 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
KR20220044563A (ko) 2019-08-05 2022-04-08 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN111411066B (zh) * 2020-03-30 2022-08-23 江南大学 一种双途径复合产神经氨酸枯草芽孢杆菌及构建方法
KR20220029524A (ko) * 2020-08-31 2022-03-08 (주)메디톡스 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
US12234297B2 (en) 2023-07-13 2025-02-25 Phylaxis Bioscience, Llc IgE binding proteins and uses thereof
CN117467016B (zh) * 2023-12-27 2024-03-12 北京索莱宝科技有限公司 人IgA的抗体、抗体组合及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
ATE121299T1 (de) 1987-12-31 1995-05-15 Tanox Biosystems Inc Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
DE69126607T2 (de) * 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
WO1996012740A1 (en) * 1994-10-25 1996-05-02 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
DK2000481T3 (en) * 2003-02-01 2016-06-06 Tanox Inc High affinity anti-human IgE antibodies
CN1926149A (zh) * 2004-02-02 2007-03-07 泰勒公司 新的IgE表位的鉴别
US20060122377A1 (en) 2004-02-19 2006-06-08 Genentech, Inc. CDR-repaired antibodies
AU2006297304B2 (en) * 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體

Also Published As

Publication number Publication date
KR101555068B1 (ko) 2015-10-06
TWI464178B (zh) 2014-12-11
RS53402B (sr) 2014-10-31
JP5723594B2 (ja) 2015-05-27
CR11035A (es) 2009-12-03
EP2644621A1 (en) 2013-10-02
HRP20140661T1 (hr) 2014-10-10
IL200752A0 (en) 2010-05-17
DK2132230T3 (da) 2014-06-30
JP2010521989A (ja) 2010-07-01
US20140115729A1 (en) 2014-04-24
CN101679528A (zh) 2010-03-24
EP2132230A2 (en) 2009-12-16
CN103554263A (zh) 2014-02-05
EP2132230B1 (en) 2014-04-16
CN101679528B (zh) 2013-11-06
RU2009138932A (ru) 2011-04-27
AU2008228778A1 (en) 2008-09-25
US8618274B2 (en) 2013-12-31
PE20090726A1 (es) 2009-06-23
CA2681341A1 (en) 2008-09-25
US20090010924A1 (en) 2009-01-08
AU2008228778B2 (en) 2014-05-22
RU2500686C2 (ru) 2013-12-10
US20120149881A1 (en) 2012-06-14
PL2132230T3 (pl) 2014-09-30
ECSP099645A (es) 2009-10-30
UA102994C2 (ru) 2013-09-10
ZA201205868B (en) 2014-04-30
EP2644621B1 (en) 2017-12-13
CO6241138A2 (es) 2011-01-20
US8632775B2 (en) 2014-01-21
WO2008116149A3 (en) 2008-11-06
PE20140771A1 (es) 2014-07-07
US20120144512A1 (en) 2012-06-07
TW200848432A (en) 2008-12-16
MX2009010092A (es) 2010-02-09
US20120177635A1 (en) 2012-07-12
CL2008000839A1 (es) 2008-09-26
SI2132230T1 (sl) 2014-07-31
US8071097B2 (en) 2011-12-06
US20120178127A1 (en) 2012-07-12
JP2015017103A (ja) 2015-01-29
ES2478242T3 (es) 2014-07-21
JP2017048190A (ja) 2017-03-09
CN103554263B (zh) 2016-09-28
HK1194743A1 (zh) 2014-10-24
NZ580553A (en) 2012-05-25
PT2132230E (pt) 2014-07-17
MA31312B1 (fr) 2010-04-01
KR20100015754A (ko) 2010-02-12
WO2008116149A2 (en) 2008-09-25
CY1115257T1 (el) 2017-01-04
US8586040B2 (en) 2013-11-19
BRPI0808291A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
AR066198A1 (es) Anticuerpos anti ige apoptoticos
ECSP21083044A (es) Moléculas de unión a cd19 y usos de las mismas
MX2017002459A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
CL2008003037A1 (es) Anticuerpo que se une especificamente a il-4; moleculas de acido nucleico, celulas huesped; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para tratar cancer, entre otras enfermedades.
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
MX2021013608A (es) Composiciones y métodos de fabricacion de celulas t.
EA201070479A1 (ru) Человеческие антиамилоидные антитела, композиции, способы и их применение
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
CL2008003361A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden.
SV2006002513A (es) Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp
CL2008001826A1 (es) Metodos y composicion para el tratamiento de enfermedades alergicas anticuerpo anti-receptor de linfopoyetina estromal timica humana (tslp) o porcion de enlace de antigeno del mismo; polinucleotido que lo codifica; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o trastorno inflamatorio en un sujeto
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
UA109633C2 (uk) Антитіло людини проти тканинного фактора
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
AR078111A1 (es) Anticuerpos del antigeno carcinoembrionario (cea)
AR063840A1 (es) Anticuerpos humanos monoclonales para btla y metodos de uso
EA200971056A1 (ru) ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx®
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
AR117735A1 (es) ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
WO2012037196A8 (en) METHODS OF TREATING AUTOIMMUNE DISEASES WITH ANTI-FCεRI ANTIBODIES
AR118957A1 (es) Moléculas de unión a cd19 y usos de las mismas
AR101721A1 (es) Anticuerpos y receptores de antígenos quiméricos específicos para cd19

Legal Events

Date Code Title Description
FB Suspension of granting procedure